Nacuity Pharmaceuticals doses first patient in Phase 3 Usher RP trial

The Fort Worth biotech has initiated its SLO-RP Preserve Phase 3 study of NPI-001 for retinitis pigmentosa linked to Usher syndrome, with sites

A bright medical examination room features a white DEX medical imaging machine with blue LED lighting and a cream-colored patient table, set against a blurred background with shelves, a plant, and a dual-monitor workstation.

Nacuity Pharmaceuticals has dosed the first participant in SLO-RP Preserve, its global confirmatory Phase 3 trial evaluating NPI-001 for retinitis pigmentosa (RP) associated with Usher syndrome. The milestone, announced on 28 October 2026, moves the Fort Worth-based clinical-stage company into the final stage of development for a condition that currently has no approved therapy capable of slowing photoreceptor degeneration.

The 24-month, randomised, double-masked study (NCT07710196) will enrol up to 80 adult participants across sites in the United States and Australia, including the Inherited Retinal Degeneration Clinic at the Retina Foundation of the Southwest in Dallas. Patients will self-administer an NPI-001 or placebo tablet twice daily and complete nine in-clinic visits over approximately two years.

The candidate

NPI-001 is a proprietary, GMP-grade formulation of N-acetylcysteine amide (NACA), a small-molecule antioxidant designed to reduce oxidative stress in retinal tissue. Preclinical data indicate that the compound boosts glutathione, the body's primary endogenous antioxidant, thereby limiting damage to photoreceptors. The oral tablet formulation is positioned by the company as straightforward to self-administer, an important consideration for a patient population that often also experiences hearing loss as part of the Usher syndrome phenotype.

NPI-001 holds FDA Breakthrough Therapy, Fast Track and Orphan Drug designations for RP, the last of which confers seven years of US regulatory exclusivity upon approval. Halden Conner, chairman, chief executive and co-founder of Nacuity, described the first patient dose as "a significant milestone for Nacuity and, more importantly, for the Usher syndrome community," and said the company aims to deliver a "potential disease-modifying therapy" for this population.

Mark Pennesi, chief medical officer of the Retina Foundation and principal investigator of the trial, said the study builds on "encouraging findings observed to date," referring to Phase 2 results that the company says informed the confirmatory programme design, though full Phase 2 data were not released with this announcement.

Market and regulatory context

Inherited retinal dystrophies represent a small but scientifically active corner of ophthalmology, with gene therapy attracting most of the investment in recent years. Spark Therapeutics' Luxturna, approved by the FDA in 2017 for RPE65 mutation-associated retinal dystrophy, remains the only gene therapy approved for an inherited retinal disease in the US, but its addressable population is narrow. Usher syndrome-related RP has a distinct genetic architecture and a broader prevalence, making a pharmacological intervention with an oral route of administration commercially attractive if efficacy is demonstrated.

The oxidative stress mechanism underpins several other programmes in development across ophthalmology and neurology, but NPI-001's Breakthrough Therapy designation suggests the FDA has seen sufficiently differentiated preliminary evidence to warrant expedited development collaboration. A completed Phase 3 dataset is typically the last substantive data package before a New Drug Application, meaning Nacuity's next major milestone will be interim safety and tolerability reads as enrolment progresses across its multi-site network.

Nacuity is backed by Foundation Fighting Blindness and its venture arm, the Gund Vision Fund. The company has not disclosed the trial's budget or a target NDA filing timeline beyond confirming the 24-month study duration.